No connection

Search Results

ASRT vs GOSS

ASRT
Assertio Holdings, Inc.
BEARISH
Price
$11.66
Market Cap
$74.8M
Sector
Healthcare
AI Confidence
85%
GOSS
Gossamer Bio, Inc.
BEARISH
Price
$0.37
Market Cap
$87.2M
Sector
Healthcare
AI Confidence
95%

Valuation

P/E Ratio
ASRT
--
GOSS
--
Forward P/E
ASRT
7.77
GOSS
-2.23
P/B Ratio
ASRT
0.71
GOSS
-0.71
P/S Ratio
ASRT
0.54
GOSS
1.8
EV/EBITDA
ASRT
1.98
GOSS
-0.94

Profitability

Gross Margin
ASRT
65.47%
GOSS
100.0%
Operating Margin
ASRT
28.72%
GOSS
-333.65%
Profit Margin
ASRT
-21.06%
GOSS
0.0%
ROE
ASRT
-24.48%
GOSS
--
ROA
ASRT
-4.17%
GOSS
-41.86%

Growth

Revenue Growth
ASRT
69.4%
GOSS
47.1%
Earnings Growth
ASRT
--
GOSS
--

Financial Health

Debt/Equity
ASRT
0.38
GOSS
--
Current Ratio
ASRT
1.58
GOSS
2.64
Quick Ratio
ASRT
1.41
GOSS
2.36

Dividends

Dividend Yield
ASRT
--
GOSS
--
Payout Ratio
ASRT
0.0%
GOSS
0.0%

AI Verdict

ASRT BEARISH

ASRT's Piotroski F-Score of 2/9 indicates severe financial distress, with weak profitability, negative ROE and ROA, and inconsistent earnings performance. The absence of an Altman Z-Score raises concern about potential bankruptcy risk, especially given negative earnings and high revenue volatility. Despite strong revenue growth (69.4% YoY) and a low price-to-sales ratio (0.54), the company trades at a significant discount due to deep operational losses and poor capital efficiency. Insider selling activity and a 5-year price decline of 80.4% further undermine confidence. The stock's current valuation appears unsustainable without a clear path to sustained profitability.

Strengths
69.4% YoY revenue growth indicates strong top-line momentum
High gross margin of 65.47% suggests strong pricing power or cost control
Low price-to-sales ratio (0.54) implies potential undervaluation on a revenue basis
Risks
Piotroski F-Score of 2/9 signals extreme financial weakness and distress
Negative ROE (-24.48%) and ROA (-4.17%) indicate poor return on capital
Persistent net losses (profit margin -21.06%) and inconsistent earnings surprises
GOSS BEARISH

GOSS exhibits critical financial distress, highlighted by a Piotroski F-Score of 0/9, indicating the weakest possible fundamental health. The company suffers from negative equity (Price/Book of -0.71) and an unsustainable operating margin of -333.65%. Despite positive revenue growth, the stock is in a catastrophic technical death spiral, losing over 85% of its value in the last six months. The massive discrepancy between the current price ($0.37) and the analyst target ($3.69) suggests a significant lag in analyst updates or extreme speculative optimism not supported by the deterministic data.

Strengths
Strong YoY revenue growth of 47.10%
Healthy short-term liquidity with a Current Ratio of 2.64
Quick Ratio of 2.36 suggests immediate obligations can be met
Risks
Negative Book Value (P/B -0.71) indicating liabilities exceed assets
Piotroski F-Score of 0/9 signals severe fundamental deterioration
Extreme price decay with a 5-year decline of 95.6%

Compare Another Pair

ASRT vs GOSS: Head-to-Head Comparison

This page compares Assertio Holdings, Inc. (ASRT) and Gossamer Bio, Inc. (GOSS) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile